home · filing · 0001628280-24-042833
8-K filed October 15, 2024, 7:59 PM ET
ticker CCCC
CIK 0001662579
leadership
confidence high
sentiment neutral
materiality 0.55
C4 Therapeutics appoints Paige Mahaney as CSO; Stewart Fisher retires effective Oct 28
C4 Therapeutics, Inc.
Paige Mahaney, Ph.D., appointed Chief Scientific Officer effective October 28, 2024; succeeds Stewart Fisher.
Fisher will remain as Senior Scientific Advisor through Dec 31, 2024, then consultant through Dec 31, 2025.
Mahaney joins from Exelixis; receives $510K base salary, $150K sign-on bonus, and 345,600 stock options.
Fisher's retirement not due to any disagreement; entered consulting agreement for continued vesting of equity.
Mahaney brings over 25 years pharma experience, most recently SVP of drug discovery at Exelixis.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
Stewart Fisher
Chief Scientific Officer
CCCC ·
C4 Therapeutics, Inc.
Effective 2024-10-28
Successor Paige Mahaney
Filed October 15, 2024, 7:59 PM ET
On October 1, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.
Appointed
Paige Mahaney
Chief Scientific Officer
CCCC ·
C4 Therapeutics, Inc.
Effective 2024-10-28
Filed October 15, 2024, 7:59 PM ET
On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stewart Fisher retired as Chief Scientific Officer at C4 Therapeutics, Inc..
Action retired
Role Chief Scientific Officer
Exact text from the filing
On October 1, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paige Mahaney was appointed as Chief Scientific Officer at C4 Therapeutics, Inc..
Action appointed
Role Chief Scientific Officer
Exact text from the filing
On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.
View on SEC.gov
Source: SEC EDGAR
accession 0001628280-24-042833
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.